Here are three things to know about the deal.
1. The transaction will add Sucampo’s constipation and experimental rare-disease drugs to Mallinckrodt’s business.
2. The additions will help diversify Mallinckrodt’s products from controversial drugs bringing in most of its revenue, Bloomberg reports. Mallinckrodt’s autoimmune and rare disease drug Acthar drew backlash for its high price, while its infant-respiratory drug INOmax lost a September court ruling and may face generic versions.
3. In addition, the Justice Department is probing Mallinckrodt and other opioid drugmakers in an effort to combat the opioid epidemic, the report states.
More articles on supply chain:
Teen inspires Dignity Health CEO to cut plastic straw use across system’s 39 hospitals
4 components critical to staff satisfaction
5 latest FDA approvals
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.